MedTrace Logo

Nicotine Effects on Endophenotypes of Schizophrenia

NCT01315002 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2015-01-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the effects of nicotine on cognition with the following schizophrenia endophenotypes: prepulse inhibition, antisaccades, the continuous performance test, spatial working memory and a verbal memory task. Schizophrenia patients, unaffected first-degree relatives of schizophrenia patients and healthy controls receive transdermal nicotine in a double-blind, placebo-controlled, crossover study.

Conditions

Interventions

DRUG

Transdermal nicotine patch

7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)

DRUG

Placebo patch

Placebo patch

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Michael Wagner, Prof. Dr. · University Hospital, Bonn

  • Wolfgang Maier, Prof. Dr. · University Hospital, Bonn

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2012-03-31
Completion
2012-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01315002 on ClinicalTrials.gov